Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

BACKGROUND: Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, David, Stenning, Sally P, Smyth, Elizabeth C, Okines, Alicia F, Allum, William H, Rowley, Sam, Stevenson, Laura, Grabsch, Heike I, Alderson, Derek, Crosby, Thomas, Griffin, S Michael, Mansoor, Wasat, Coxon, Fareeda Y, Falk, Stephen J, Darby, Suzanne, Sumpter, Kate A, Blazeby, Jane M, Langley, Ruth E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337626/
https://www.ncbi.nlm.nih.gov/pubmed/28163000
http://dx.doi.org/10.1016/S1470-2045(17)30043-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337626/
https://www.ncbi.nlm.nih.gov/pubmed/28163000
http://dx.doi.org/10.1016/S1470-2045(17)30043-8

Ejemplares similares